Home » Shire Requests FDA Hearing, Will Keep Marketing ProAmatine
Shire Requests FDA Hearing, Will Keep Marketing ProAmatine
Shire will keep its low blood pressure treatment ProAmatine on the market while the FDA moves forward with a formal process that could result in withdrawal of the drug’s approval, the company said this week. Shire has requested a hearing and plans to continue to make ProAmatine (midodrine) accessible to patients after Sept. 30, company spokesman Matthew Cabrey said. Last November, Shire notified the FDA that it planned to stop marketing the drug by that date. FDA spokeswoman Ayse Yeaton said the agency will continue to allow access to the drug while the necessary postmarket data are collected and legal issues get sorted out.
Drug Industry Daily
Drug Industry Daily
Upcoming Events
-
23May
-
30May
-
13Jun
-
20Jun
-
21Oct